The Indian company Biological E Lt ("Biological I") intends to sign a contract with the American corporation Johnson & Johnson ("Johnson & Johnson") on the production of up to 600 million doses of its vaccines against coronavirus at its enterprises annually. The Times of India reported this on Wednesday.
“We are aiming to sign a contract with Johnson & Johnson for the release of up to 600 million doses of COVID-19 vaccines from this corporation, in addition to our own coronavirus drug, the volume of which will be approximately 1 billion doses,” the publication quotes the words of the chapter "Biological I"
The time of signing the contract has not been finally determined. It is also not yet known exactly when the so-called interim study of the safety and immunogenicity of the Johnson & Johnson vaccine in India, which is mandatory for all foreign medicines, will take place.
According to representatives of the Ministry of Health of the republic, "Johnson & Johnson" is ready to produce its vaccine in India. It was developed by Baylor College of Medicine in Houston and the American company Danavax Technologies (Denavax Technologies).
Vaccination campaign in India
The Ministry of Health of India believes that the release of the drug by the Johnson & Johnson corporation is necessary to increase the pace of the nationwide, "largest in the world" vaccination campaign against coronavirus. It began on January 16, and to date, more than 6.6 million people have received vaccinations in the country. It is planned that at the first stage about 30 million people will receive the vaccine - 10 million medical workers and 20 million employees at risk - police officers, military personnel, civil defense officials. Then people over 50 years old and people under the age of 50 years with concomitant diseases (about 270 million people in total) will be vaccinated.
India plans to vaccinate about 300 million people against coronavirus by July.
At the first stage, vaccinations are given with two vaccines - Covishield, developed by the British-Swedish company AstraZeneca and Oxford University, and Covaxin, by the Indian company Bharat Biotech. Both vaccines are produced in India. In addition, several other drugs are undergoing clinical trials in the country at various stages, including the Russian Sputnik V vaccine.